- Home
- AMGN vs UL Comparison
AMGN vs UL Comparison
Compare AMGN & UL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMGN
- UL
- Stock Information
- Founded
- AMGN 1980
- UL 1930
- Country
- AMGN United States
- UL United Kingdom
- Employees
- AMGN N/A
- UL 128377
- Industry
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- UL Package Goods/Cosmetics
- Sector
- AMGN Health Care
- UL Consumer Discretionary
- Exchange
- AMGN Nasdaq
- UL Nasdaq
- Market Cap
- AMGN 147.3B
- UL 141.4B
- IPO Year
- AMGN N/A
- UL N/A
- Fundamental
- Price
- AMGN $263.38
- UL $57.14
- Analyst Decision
- AMGN Buy
- UL Buy
- Analyst Count
- AMGN 22
- UL 5
- Target Price
- AMGN $329.05
- UL $60.00
- AVG Volume (30 Days)
- AMGN 4.7M
- UL 2.5M
- Earning Date
- AMGN 02-04-2025
- UL 02-06-2025
- Dividend Yield
- AMGN 3.62%
- UL 3.33%
- EPS Growth
- AMGN N/A
- UL N/A
- EPS
- AMGN 7.83
- UL 2.82
- Revenue
- AMGN $32,534,000,000.00
- UL $64,601,950,064.00
- Revenue This Year
- AMGN $20.04
- UL $2.95
- Revenue Next Year
- AMGN $3.41
- UL $3.20
- P/E Ratio
- AMGN $33.62
- UL $19.94
- Revenue Growth
- AMGN 21.25
- UL N/A
- 52 Week Low
- AMGN $253.30
- UL $46.46
- 52 Week High
- AMGN $346.85
- UL $65.87
- Technical
- Relative Strength Index (RSI)
- AMGN 31.29
- UL 31.26
- Support Level
- AMGN $253.30
- UL $58.53
- Resistance Level
- AMGN $280.00
- UL $59.90
- Average True Range (ATR)
- AMGN 5.95
- UL 0.63
- MACD
- AMGN -0.21
- UL -0.10
- Stochastic Oscillator
- AMGN 35.90
- UL 8.88
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
About UL Unilever PLC
Unilever is a diversified personal-care (52% of 2022 sales by value), homecare (14%), and packaged food (34%) company. Its brands include Knorr soups and sauces, Hellmann's mayonnaise, Axe and Dove skin products, and the TRESemmé haircare brand. The firm has been acquisitive in recent years; notable purchases include Paula's Choice, Liquid I.V., Horlicks, Garancia, and The Vegetarian Butcher.